Table 2 Univariable analysis of potential preditive factors of progression-free survival
From: Accelerated hyperfractionation plus temozolomide in glioblastoma
Univariable analysis | Multivariable analysis | ||||||
|---|---|---|---|---|---|---|---|
Variable | HR | 95 % CI | p | Median PFS [m] | HR | 95 % CI | p |
Age (< vs. > = median of 61 years) | 1.08 | 0.75–1.55 | 0.69 | 6 vs. 6 | – | – | – |
Gender (m vs. f) | 0.68 | 0.46–1.01 | 0.05 | 6 vs. 9 | 0.57 | 0.35–0.92 | 0.022 (*) |
KPS (< vs. > = median of 70 %) | 0.5 | 0.34–0.72 | <0.001 (*) | 4 vs. 9 | 0.5 | 0.33–0.78 | 0.002 (*) |
MGMT-status (methylated vs. unmethylated) | 1.46 | 0.97–2.2 | 0.07 | 9 vs. 6 | 1.61 | 1.03–2.52 | 0.036 (*) |
Localization (other vs. central) | 1.51 | 0.76–3 | 0.24 | 6 vs. 5 | – | – | – |
PTV (< vs. > = median of 337 ccm) | 1.13 | 0.79–1.62 | 0.51 | 7 vs. 6 | – | – | – |
Subtotal resection or biopsy vs. gross total resection | 0.71 | 0.49–1.02 | 0.07 | 4 vs. 8 | – | – | – |
Fractionation regimen (NFRT vs. AHFRT) | 1.01 | 0.95–1.01 | 0.95 | 7 vs. 6 | – | – | – |